APLLTD vs ERIS: Stock Comparison
ERIS LIFESCIENCES is the larger company by market capitalisation. ALEMBIC PHARMA shows a lower P/E, a higher ROE and a higher dividend yield, while ERIS LIFESCIENCES shows faster revenue growth and a higher net margin. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
APLLTD leads 6; ERIS leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | APLLTD | ERIS |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | APLLTD | ERIS |
|---|---|---|
| Live Price | ₹810.95 | ₹1,355.5 |
| Day Change | -0.67% | -0.08% |
| Volume | 1.19 L | 24,968 |
| 52-Week High | ₹998 | ₹1,740 |
| 52-Week Low | ₹635.8 | ₹1,200 |
| Distance from 52W High | -18.74% | -22.1% |
Valuation
| Metric | APLLTD | ERIS |
|---|---|---|
| Market Cap | ₹15,931 Cr | ₹18,777 Cr |
| P/E Ratio | 22.97x | 28.98x |
| P/B Ratio | 2.81x | 4.81x |
| EPS | ₹8.8 | ₹10.28 |
| Book Value | ₹288.41 | ₹281.12 |
| Dividend Yield | 1.48% | 0.53% |
Growth
| Metric | APLLTD | ERIS |
|---|---|---|
| Revenue Growth (TTM YoY) | 4.4% | 7.1% |
| EPS Growth (TTM YoY) | 29.2% | 200% |
| Qtr Sales Growth | 15.08% | 96.68% |
| Qtr Profit Growth | -12.49% | 196.73% |
Profitability & Leverage
| Metric | APLLTD | ERIS |
|---|---|---|
| ROE | 11.4% | 7.64% |
| ROCE | 10.99% | 6.96% |
| Net Margin | 8.98% | 19.89% |
| Operating Margin | 11.13% | 29.73% |
| Debt to Equity | 0.2x | 0.65x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | APLLTD | ERIS |
|---|---|---|
| Promoter Holding | 69.36%▲ 0.13 pp | 54.14%▲ 0.22 pp |
| FII Holding | 4.18%▼ 0.07 pp | 5.75%▼ 0.64 pp |
| DII Holding | 15.94%▼ 0.24 pp | 20.72%▲ 0.37 pp |
| Public Holding | 10.01%▲ 0.18 pp | 19.4%▲ 0.07 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: ALEMBIC PHARMA and ERIS LIFESCIENCES.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.